Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Conflict of interest: COI declared see note COI notes: A.H.W has served on advisory boards for Novartis, Astra Zeneca, Astellas, Janssen, Amgen, Roche, Pfizer, Abbvie, Servier, Gilead, BMS, Macrogenics and Agios; receives research funding to the Institution from Novartis, Abbvie, Servier, Janssen, BMS, Syndax, Astex, Astra Zeneca, Amgen; serves on speaker's bureaus for Abbvie, Novartis, BMS, Servier, Astellas. A.H.W. and N.S.A., are employees of the Walter and Eliza Hall Institute, which receives milestone and royalty payments related to venetoclax. Preprint server: No; Author contributions and disclosures: A.H.W. and S.L. designed the research; A.I. designed and validated the PCR-NGS assay; A.I., N.S.A., N.P., J.J., M.R., M.M. and A.G. sequenced and analyzed the samples or provided other molecular analysis tools and interpretation; J.O. and S.L. performed clinical data collection; S.L. performed the statistical analysis; S.L., R.D., J.O., I.S.T., C.C.C., A.B., D.R., Z.H.Y., K.G., I.T., S.J., N.H.R. and A.H.W. contributed patients or analyzed and interpreted data; S.L. and A.H.W. wrote the manuscript; all authors read and approved the